Galunisertib, a new TGFβRI inhibitor, has been used alone and in combination with other treatments in the clinic.[14] In a subset of patients with advanced HCC treated with galunisertib, decreases in the circulating AFP and TGF‐β1 levels were connected with longer OS times.[11] In our study, we verified the therapeutic effect of galunisertib monotherapy in HCC in different mouse models. Here, TGFB1 is linked to hepatocellular carcinoma.